Oncology Today with Dr Neil Love

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:
Introduction (0:00)
Trials in Progress (1:12)
Chronic Lymphocytic Leukemia (7:09)
Diffuse Large B-Cell Lymphoma (32:35)
Mantle Cell Lymphoma (58:25)
Follicular Lymphoma (1:14:49)

CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic:
Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A Ledermann

CME information and select publications

Featuring an interview with Dr Douglas W Sborov, including the following topics:
DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)

CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:
Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)
CNS activity of TROP2-directed antibody-drug conjugates (5:36)
Autoimmune considerations with immunotherapy (10:09)
Treatment of oligoprogressive advanced breast cancer (17:31)

CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:
First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)
First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)
Adverse events (19:39)

CME information and select publications